Novo Nordisk on Wednesday announced its second quarter earnings for 2024.
Novo Nordisk on Wednesday posted weaker-than-expected net profit in the second quarter and trimmed its operating profit outlook.
The pharmaceutical giant said its net profit came in at 20.05 billion Danish kroner in the three months to the end of June. A LSEG aggregate forecast had projected the figure would come in at 20.9 billion Danish kroner., the Wegovy maker had posted a net profit increase of 28% to 25.4 billion Danish kroner year on year, it said in May.Sign up for our free Olympics Headlines newsletter.
At the time, Novo Nordisk also raised its 2024 outlook slightly, bumping its sales growth projection to a range between 19% and 27% at constant exchange rates, as well as raising its operating growth forecast to a 22% to 30% interval. The adjustment was linked to prior-year growth net estimates in the U.S., the company said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlookNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
Read more »
Novo Nordisk's Wegovy wins EU backing for reducing heart risksNovo Nordisk's Wegovy has received backing from the EU's medical regulator to expand the weight loss drug's use to reducing the rise of serious heart events.
Read more »
UK Approves Novo Nordisk’s Wegovy As First-Of-Its-Kind Treatment To Lower Heart RisksTy Roush is a New York City-based breaking news reporter who frequently covers Russia’s invasion of Ukraine, the automotive industry and sports money. He joined Forbes in 2022 and has covered Exxon acquiring Pioneer for nearly $60 billion, a mysterious respiratory illness affecting dogs across the U.S.
Read more »
Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatmentThe U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy drug to reduce the risk of obese adults suffering from serious heart problems or strokes.
Read more »
Novo Nordisk’s Wegovy Weight-Loss Drug Gets Approval in ChinaDemand for weight-loss drugs is surging in China, where the proportion of overweight and obese adults reached almost 51% in 2022
Read more »
Lilly, Novo Nordisk Battle for Weight-loss Market Lands At the Pharmacy ShelfAs Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is...
Read more »